[1]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 2013.
[2]
Maraz, A.; Hende, B.; Urbán, R.; Demetrovics, Z. Pathological grooming: Evidence for a single factor behind trichotillomania, skin picking and nail biting. PLoS One, 2017, 12(9)e0183806 [http://dx.doi.org/10.1371/journal.pone.0183806]. [PMID: 28902896].
[3]
Grant, J.E.; Chamberlain, S.R. Trichotillomania. Am. J. Psychiatry, 2016, 173(9), 868-874. [http://dx.doi.org/10.1176/appi.ajp.2016.15111432]. [PMID: 27581696].
[4]
Grant, J.E.; Odlaug, B.L.; Chamberlain, S.R.; Keuthen, N.J.; Lochner, C.; Stein, D.J. Skin picking disorder. Am. J. Psychiatry, 2012, 169(11), 1143-1149. [http://dx.doi.org/10.1176/appi.ajp.2012.12040508]. [PMID: 23128921].
[5]
Malone, A.J.; Massler, M. Index of nailbiting in children. J. Abnorm. Psychol., 1952, 47(2), 193-202. [PMID: 14937953].
[6]
Pennington, L.A. The incidence of nail biting among adults. Am. J. Psychiatry, 1945, 102, 241-244. [http://dx.doi.org/10.1176/ajp.102.2.241].
[7]
Ballinger, B.R. The prevalence of nail-biting in normal and abnormal populations. Br. J. Psychiatry, 1970, 117(539), 445-446. [http://dx.doi.org/10.1192/bjp.117.539.445]. [PMID: 5481208].
[8]
Chamberlain, S.R.; Menzies, L.; Sahakian, B.J.; Fineberg, N.A. Lifting the veil on trichotillomania. Am. J. Psychiatry, 2007, 164(4), 568-574. [http://dx.doi.org/10.1176/ajp.2007.164.4.568]. [PMID: 17403968].
[9]
Wilhelm, S.; Keuthen, N.J.; Deckersbach, T.; Engelhard, I.M.; Forker, A.E.; Baer, L.; O’Sullivan, R.L.; Jenike, M.A. Self-injurious skin picking: clinical characteristics and comorbidity. J. Clin. Psychiatry, 1999, 60(7), 454-459. [http://dx.doi.org/10.4088/JCP.v60n0707]. [PMID: 10453800].
[10]
Bakwin, H. Nail-biting in twins. Dev. Med. Child Neurol., 1971, 13(3), 304-307. [http://dx.doi.org/10.1111/j.1469-8749.1971.tb03265.x]. [PMID: 5093291].
[11]
Williams, W.A.; Potenza, M.N. The neurobiology of impulse control disorders. Rev. Bras. Psiquiatr., 2008, 30(Suppl. 1), S24-S30. [http://dx.doi.org/10.1590/S1516-44462008005000003]. [PMID: 18278382].
[12]
Grant, J.E.; Odlaug, B.L.; Chamberlain, S.R. Neural and psychological underpinnings of gambling disorder: A review. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016, 65, 188-193. [http://dx.doi.org/10.1016/j.pnpbp.2015.10.007]. [PMID: 26497079].
[13]
Isobe, M.; Redden, S.A.; Keuthen, N.J.; Stein, D.J.; Lochner, C.; Grant, J.E.; Chamberlain, S.R. Striatal abnormalities in trichotillomania: A multi-site MRI analysis. Neuroimage Clin., 2018, 17, 893-898. [http://dx.doi.org/10.1016/j.nicl.2017.12.031]. [PMID: 29515968].
[14]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 2009, 6(7)e1000097 [http://dx.doi.org/10.1371/journal.pmed.1000097]. [PMID: 19621072].
[15]
Ninan, P.T.; Rothbaum, B.O.; Marsteller, F.A.; Knight, B.T.; Eccard, M.B. A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J. Clin. Psychiatry, 2000, 61(1), 47-50. [http://dx.doi.org/10.4088/JCP.v61n0111]. [PMID: 10695646].
[16]
Swedo, S.E.; Leonard, H.L.; Rapoport, J.L.; Lenane, M.C.; Goldberger, E.L.; Cheslow, D.L. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N. Engl. J. Med., 1989, 321(8), 497-501. [http://dx.doi.org/10.1056/NEJM198908243210803]. [PMID: 2761586].
[17]
Leonard, H.L.; Lenane, M.C.; Swedo, S.E.; Rettew, D.C.; Rapoport, J.L. A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). Arch. Gen. Psychiatry, 1991, 48(9), 821-827. [http://dx.doi.org/10.1001/archpsyc.1991.01810330045007]. [PMID: 1929772].
[18]
Bloch, M.H.; Landeros-Weisenberger, A.; Dombrowski, P.; Kelmendi, B.; Wegner, R.; Nudel, J.; Pittenger, C.; Leckman, J.F.; Coric, V. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol. Psychiatry, 2007, 62(8), 839-846. [http://dx.doi.org/10.1016/j.biopsych.2007.05.019]. [PMID: 17727824].
[19]
Swedo, S.E.; Leonard, H.L.; Rapoport, J.L.; Lenane, M.C.; Goldberger, E.L.; Cheslow, D.L. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N. Engl. J. Med., 1989, 321(8), 497-501. [http://dx.doi.org/10.1056/NEJM198908243210803]. [PMID: 2761586].
[20]
Jenike, M.A. Obsessive-compulsive and related disorders: A hidden epidemic. N. Engl. J. Med., 1989, 321(8), 539-541. [http://dx.doi.org/10.1056/NEJM198908243210811]. [PMID: 2761591].
[21]
Dawber, R. Self-induced hair loss. Semin. Dermatol., 1985, 4, 53-57.
[22]
Christenson, G.A.; Mackenzie, T.B.; Mitchell, J.E.; Callies, A.L. A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am. J. Psychiatry, 1991, 148(11), 1566-1571. [http://dx.doi.org/10.1176/ajp.148.11.1566]. [PMID: 1928474].
[23]
Streichenwein, S.M.; Thornby, J.I. A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am. J. Psychiatry, 1995, 152(8), 1192-1196. [http://dx.doi.org/10.1176/ajp.152.8.1192]. [PMID: 7625469].
[24]
Stein, D.J.; Chamberlain, S.R.; Fineberg, N. An A-B-C model of habit disorders: hair-pulling, skin-picking, and other stereotypic conditions. CNS Spectr., 2006, 11(11), 824-827. [http://dx.doi.org/10.1017/S1092852900014978]. [PMID: 17075554].
[25]
Stein, D.J.; Flessner, C.A.; Franklin, M.; Keuthen, N.J.; Lochner, C.; Woods, D.W. Is trichotillomania a stereotypic movement disorder? An analysis of body-focused repetitive behaviors in people with hair-pulling. Ann. Clin. Psychiatry, 2008, 20(4), 194-198. [http://dx.doi.org/10.1080/10401230802435625]. [PMID: 19034750].
[26]
Cullen, B.A.; Samuels, J.F.; Bienvenu, O.J.; Grados, M.; Hoehn-Saric, R.; Hahn, J.; Liang, K.Y.; Wellen, D.; Dees, M.; Riddle, M.A.; Nestadt, G. The relationship of pathologic skin picking to obsessive-compulsive disorder. J. Nerv. Ment. Dis., 2001, 189(3), 193-195. [http://dx.doi.org/10.1097/00005053-200103000-00010]. [PMID: 11277358].
[27]
Grant, J.E.; Odlaug, B.L.; Kim, S.W. A clinical comparison of pathologic skin picking and obsessive-compulsive disorder. Compr. Psychiatry, 2010, 51(4), 347-352. [http://dx.doi.org/10.1016/j.comppsych.2009.10.006]. [PMID: 20579505].
[28]
Coric, V.; Taskiran, S.; Pittenger, C.; Wasylink, S.; Mathalon, D.H.; Valentine, G.; Saksa, J.; Wu, Y.T.; Gueorguieva, R.; Sanacora, G.; Malison, R.T.; Krystal, J.H. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol. Psychiatry, 2005, 58(5), 424-428. [http://dx.doi.org/10.1016/j.biopsych.2005.04.043]. [PMID: 15993857].
[29]
Lafleur, D.L.; Pittenger, C.; Kelmendi, B.; Gardner, T.; Wasylink, S.; Malison, R.T.; Sanacora, G.; Krystal, J.H.; Coric, V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl.), 2006, 184(2), 254-256. [http://dx.doi.org/10.1007/s00213-005-0246-6]. [PMID: 16374600].
[30]
Grant, J.E.; Odlaug, B.L.; Kim, S.W. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: A double-blind, placebo-controlled study. Arch. Gen. Psychiatry, 2009, 66(7), 756-763. [http://dx.doi.org/10.1001/archgenpsychiatry.2009.60]. [PMID: 19581567].
[31]
Leach, M.J.; Marden, C.M.; Miller, A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia, 1986, 27(5), 490-497. [http://dx.doi.org/10.1111/j.1528-1157.1986.tb03573.x]. [PMID: 3757936].
[32]
Wang, S.J.; Sihra, T.S.; Gean, P.W. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport, 2001, 12(10), 2255-2258. [http://dx.doi.org/10.1097/00001756-200107200-00042]. [PMID: 11447345].
[33]
Frye, M.A.; Watzl, J.; Banakar, S.; O’Neill, J.; Mintz, J.; Davanzo, P.; Fischer, J.; Chirichigno, J.W.; Ventura, J.; Elman, S.; Tsuang, J.; Walot, I.; Thomas, M.A. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology, 2007, 32(12), 2490-2499. [http://dx.doi.org/10.1038/sj.npp.1301387]. [PMID: 17429412].
[34]
Grant, J.E.; Odlaug, B.L.; Chamberlain, S.R.; Kim, S.W. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. J. Clin. Psychopharmacol., 2010, 30(4), 396-403. [http://dx.doi.org/10.1097/JCP.0b013e3181e617a1]. [PMID: 20531220].
[35]
Stein, D.J.; Mullen, L.; Islam, M.N.; Cohen, L.; DeCaria, C.M.; Hollander, E. Compulsive and impulsive symptomatology in trichotillomania. Psychopathology, 1995, 28(4), 208-213. [http://dx.doi.org/10.1159/000284923]. [PMID: 7480576].
[36]
Stein, D.J.; Lochner, C. Obsessive-compulsive spectrum disorders: a multidimensional approach. Psychiatr. Clin. North Am., 2006, 29(2), 343-351. [http://dx.doi.org/10.1016/j.psc.2006.02.015]. [PMID: 16650712].
[37]
Bohne, A.; Savage, C.R.; Deckersbach, T.; Keuthen, N.J.; Wilhelm, S. Motor inhibition in trichotillomania and obsessive-compulsive disorder. J. Psychiatr. Res., 2008, 42(2), 141-150. [http://dx.doi.org/10.1016/j.jpsychires.2006.11.008]. [PMID: 17215004].
[38]
Christenson, G.A.; Mansueto, C.S. Trichotillomania: descriptive characteristics and phenomenology.Trichotillomania; Stein, D.J.; Christenson, G.A; Hollander, E., Ed.; American Psychiatric Press, Inc.: Washington, DC, 1999, pp. 1-42.
[39]
Tükel, R.; Keser, V.; Karali, N.T.; Olgun, T.O.; Calikuşu, C. Comparison of clinical characteristics in trichotillomania and obsessive-compulsive disorder. J. Anxiety Disord., 2001, 15(5), 433-441. [http://dx.doi.org/10.1016/S0887-6185(01)00074-3]. [PMID: 11583075].
[40]
Stein, D.J.; Bouwer, C.; Niehaus, D.J. Stereotypic movement disorder. J. Clin. Psychiatry, 1997, 58(4), 177-178. [http://dx.doi.org/10.4088/JCP.v58n0407f]. [PMID: 9164434].
[41]
Stein, D.J.; Hollander, E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J. Clin. Psychiatry, 1992, 53(4), 123-126. [PMID: 1532960].
[42]
Lochner, C.; Stein, D.J. Does work on obsessive-compulsive spectrum disorders contribute to understanding the heterogeneity of obsessive-compulsive disorder? Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(3), 353-361. [http://dx.doi.org/10.1016/j.pnpbp.2005.11.004]. [PMID: 16458405].
[43]
Goodman, W.K.; McDougle, C.J.; Price, L.H.; Riddle, M.A.; Pauls, D.L.; Leckman, J.F. Beyond the serotonin hypothesis: A role for dopamine in some forms of obsessive compulsive disorder? J. Clin. Psychiatry, 1990, 51(8)(Suppl.), 36-43. [PMID: 2199433].
[44]
Shapiro, A.K.; Shapiro, E. Evaluation of the reported association of obsessive-compulsive symptoms or disorder with Tourette’s disorder. Compr. Psychiatry, 1992, 33(3), 152-165. [http://dx.doi.org/10.1016/0010-440X(92)90024-K]. [PMID: 1591906].
[45]
O’Sullivan, R.L.; Rauch, S.L.; Breiter, H.C.; Grachev, I.D.; Baer, L.; Kennedy, D.N.; Keuthen, N.J.; Savage, C.R.; Manzo, P.A.; Caviness, V.S.; Jenike, M.A. Reduced basal ganglia volumes in trichotillomania measured via morphometric magnetic resonance imaging. Biol. Psychiatry, 1997, 42(1), 39-45. [http://dx.doi.org/10.1016/S0006-3223(96)00297-1]. [PMID: 9193740].
[46]
Keuthen, N.J.; Makris, N.; Schlerf, J.E.; Martis, B.; Savage, C.R.; McMullin, K.; Seidman, L.J.; Schmahmann, J.D.; Kennedy, D.N.; Hodge, S.M.; Rauch, S.L. Evidence for reduced cerebellar volumes in trichotillomania. Biol. Psychiatry, 2007, 61(3), 374-381. [http://dx.doi.org/10.1016/j.biopsych.2006.06.013]. [PMID: 16945351].
[47]
White, M.P.; Shirer, W.R.; Molfino, M.J.; Tenison, C.; Damoiseaux, J.S.; Greicius, M.D. Disordered reward processing and functional connectivity in trichotillomania: A pilot study. J. Psychiatr. Res., 2013, 47(9), 1264-1272. [http://dx.doi.org/10.1016/j.jpsychires.2013.05.014]. [PMID: 23777938].
[48]
Rauch, S.L.; Wright, C.I.; Savage, C.R.; Martis, B.; McMullin, K.G.; Wedig, M.M.; Gold, A.L.; Keuthen, N.J. Brain activation during implicit sequence learning in individuals with trichotillomania. Psychiatry Res., 2007, 154(3), 233-240. [http://dx.doi.org/10.1016/j.pscychresns.2006.09.002]. [PMID: 17321724].
[49]
Saxena, S. Neurobiology and treatment of compulsive hoarding. CNS Spectr., 2008, 13(9)(Suppl. 14), 29-36. [http://dx.doi.org/10.1017/S1092852900026912]. [PMID: 18849909].
[50]
Swedo, S.E.; Rapoport, J.L.; Leonard, H.L.; Schapiro, M.B.; Rapoport, S.I.; Grady, C.L. Regional cerebral glucose metabolism of women with trichotillomania. Arch. Gen. Psychiatry, 1991, 48(9), 828-833. [http://dx.doi.org/10.1001/archpsyc.1991.01810330052008]. [PMID: 1929773].
[51]
Stein, D.J.; van Heerden, B.; Hugo, C.; van Kradenburg, J.; Warwick, J.; Zungu-Dirwayi, N.; Seedat, S. Functional brain imaging and pharmacotherapy in trichotillomania. Single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2002, 26(5), 885-890. [http://dx.doi.org/10.1016/S0278-5846(01)00334-7]. [PMID: 12369261].
[52]
Van Ameringen, M.; Mancini, C.; Oakman, J.M.; Farvolden, P. The potential role of haloperidol in the treatment of trichotillomania. J. Affect. Disord., 1999, 56(2-3), 219-226. [http://dx.doi.org/10.1016/S0165-0327(99)00019-1]. [PMID: 10701481].
[53]
Van Ameringen, M.; Mancini, C.; Patterson, B.; Bennett, M.; Oakman, J. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J. Clin. Psychiatry, 2010, 71(10), 1336-1343. [http://dx.doi.org/10.4088/JCP.09m05114gre]. [PMID: 20441724].
[54]
Deepmala; Slattery, J.; Kumar, N.; Delhey, L.; Berk, M.; Dean, O.; Spielholz, C.; Frye, R. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci. Biobehav. Rev., 2015, 55, 294-321. [http://dx.doi.org/10.1016/j.neubiorev.2015.04.015]. [PMID: 25957927].
[55]
Moran, M.M.; McFarland, K.; Melendez, R.I.; Kalivas, P.W.; Seamans, J.K. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J. Neurosci., 2005, 25(27), 6389-6393. [http://dx.doi.org/10.1523/JNEUROSCI.1007-05.2005]. [PMID: 16000629].
[56]
Cotgreave, I.A. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv. Pharmacol., 1997, 38, 205-227. [http://dx.doi.org/10.1016/S1054-3589(08)60985-0]. [PMID: 8895810].
[57]
De Rosa, S.C.; Zaretsky, M.D.; Dubs, J.G.; Roederer, M.; Anderson, M.; Green, A.; Mitra, D.; Watanabe, N.; Nakamura, H.; Tjioe, I.; Deresinski, S.C.; Moore, W.A.; Ela, S.W.; Parks, D.; Herzenberg, L.A.; Herzenberg, L.A. N-acetylcysteine replenishes glutathione in HIV infection. Eur. J. Clin. Invest., 2000, 30(10), 915-929. [http://dx.doi.org/10.1046/j.1365-2362.2000.00736.x]. [PMID: 11029607].
[58]
Dringen, R.; Hirrlinger, J. Glutathione pathways in the brain. Biol. Chem., 2003, 384(4), 505-516. [http://dx.doi.org/10.1515/BC.2003.059]. [PMID: 12751781].
[59]
Berk, M.; Copolov, D.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Judd, F.; Katz, F.; Katz, P.; Ording-Jespersen, S.; Little, J.; Conus, P.; Cuenod, M.; Do, K.Q.; Bush, A.I. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry, 2008, 64(5), 361-368. [http://dx.doi.org/10.1016/j.biopsych.2008.03.004]. [PMID: 18436195].
[60]
Hardan, A.Y.; Fung, L.K.; Libove, R.A.; Obukhanych, T.V.; Nair, S.; Herzenberg, L.A.; Frazier, T.W.; Tirouvanziam, R. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol. Psychiatry, 2012, 71(11), 956-961. [http://dx.doi.org/10.1016/j.biopsych.2012.01.014]. [PMID: 22342106].
[61]
LaRowe, S.D.; Mardikian, P.; Malcolm, R.; Myrick, H.; Kalivas, P.; McFarland, K.; Saladin, M.; McRae, A.; Brady, K. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am. J. Addict., 2006, 15(1), 105-110. [http://dx.doi.org/10.1080/10550490500419169]. [PMID: 16449100].
[62]
Bloch, M.H.; Panza, K.E.; Grant, J.E.; Pittenger, C.; Leckman, J.F. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J. Am. Acad. Child Adolesc. Psychiatry, 2013, 52(3), 231-240. [http://dx.doi.org/10.1016/j.jaac.2012.12.020]. [PMID: 23452680].
[63]
Grant, J.E.; Chamberlain, S.R.; Redden, S.A.; Leppink, E.W.; Odlaug, B.L.; Kim, S.W. N-Acetylcysteine in the treatment of excoriation disorder: A randomized clinical trial. JAMA Psychiatry, 2016, 73(5), 490-496. [http://dx.doi.org/10.1001/jamapsychiatry.2016.0060]. [PMID: 27007062].
[64]
Benjamin, J.; Agam, G.; Levine, J.; Bersudsky, Y.; Kofman, O.; Belmaker, R.H. Inositol treatment in psychiatry. Psychopharmacol. Bull., 1995, 31(1), 167-175. [PMID: 7675981].
[65]
Camfield, D.A.; Sarris, J.; Berk, M. Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): A review of mechanistic and clinical evidence. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35(4), 887-895. [http://dx.doi.org/10.1016/j.pnpbp.2011.02.011]. [PMID: 21352883].
[66]
Mukai, T.; Kishi, T.; Matsuda, Y.; Iwata, N. A meta-analysis of inositol for depression and anxiety disorders. Hum. Psychopharmacol., 2014, 29(1), 55-63. [http://dx.doi.org/10.1002/hup.2369]. [PMID: 24424706].
[67]
Benjamin, J.; Levine, J.; Fux, M.; Aviv, A.; Levy, D.; Belmaker, R.H. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am. J. Psychiatry, 1995, 152(7), 1084-1086. [http://dx.doi.org/10.1176/ajp.152.7.1084]. [PMID: 7793450].
[68]
Kaplan, Z.; Amir, M.; Swartz, M.; Levine, J. Inositol treatment of post-traumatic stress disorder. Anxiety, 1996, 2(1), 51-52. [http://dx.doi.org/10.1002/(SICI)1522-7154(1996)2:1<51:AID-ANXI8>3.0.CO;2-G]. [PMID: 9160600].
[69]
Levine, J. Controlled trials of inositol in psychiatry. Eur. Neuropsychopharmacol., 1997, 7(2), 147-155. [http://dx.doi.org/10.1016/S0924-977X(97)00409-4]. [PMID: 9169302].
[70]
Seedat, S.; Stein, D.J. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int. Clin. Psychopharmacol., 1999, 14(6), 353-356. [http://dx.doi.org/10.1097/00004850-199911000-00005]. [PMID: 10565802].
[71]
Nierenberg, A.A.; Ostacher, M.J.; Calabrese, J.R.; Ketter, T.A.; Marangell, L.B.; Miklowitz, D.J.; Miyahara, S.; Bauer, M.S.; Thase, M.E.; Wisniewski, S.R.; Sachs, G.S. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am. J. Psychiatry, 2006, 163(2), 210-216. [http://dx.doi.org/10.1176/appi.ajp.163.2.210]. [PMID: 16449473].
[72]
Carlomagno, G.; Unfer, V. Inositol safety: clinical evidences. Eur. Rev. Med. Pharmacol. Sci., 2011, 15(8), 931-936. [PMID: 21845803].
[73]
Frey, R.; Metzler, D.; Fischer, P.; Heiden, A.; Scharfetter, J.; Moser, E.; Kasper, S. Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. J. Psychiatr. Res., 1998, 32(6), 411-420. [http://dx.doi.org/10.1016/S0022-3956(98)00033-8]. [PMID: 9844958].
[74]
Harvey, B.H.; Brink, C.B.; Seedat, S.; Stein, D.J. Defining the neuromolecular action of myo-inositol: Application to obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2002, 26(1), 21-32. [http://dx.doi.org/10.1016/S0278-5846(01)00244-5]. [PMID: 11853115].
[75]
Johnson, J.; El-Alfy, A.T. Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania. J. Adv. Res., 2016, 7(2), 169-184. [http://dx.doi.org/10.1016/j.jare.2015.05.001]. [PMID: 26966559].
[76]
Stein, D.J.; Kogan, C.S.; Atmaca, M.; Fineberg, N.A.; Fontenelle, L.F.; Grant, J.E.; Matsunaga, H.; Reddy, Y.C.J.; Simpson, H.B.; Thomsen, P.H.; van den Heuvel, O.A.; Veale, D.; Woods, D.W.; Reed, G.M. The classification of Obsessive-Compulsive and Related Disorders in the ICD-11. J. Affect. Disord., 2016, 190, 663-674. [http://dx.doi.org/10.1016/j.jad.2015.10.061]. [PMID: 26590514].
[77]
Modi, S.; Rana, P.; Kaur, P.; Rani, N.; Khushu, S. Glutamate level in anterior cingulate predicts anxiety in healthy humans: A magnetic resonance spectroscopy study. Psychiatry Res., 2014, 224(1), 34-41. [http://dx.doi.org/10.1016/j.pscychresns.2014.03.001]. [PMID: 25156662].
[78]
Ortiz, A.E.; Gassó, P.; Mas, S.; Falcon, C.; Bargalló, N.; Lafuente, A.; Lázaro, L. Association between genetic variants of serotonergic and glutamatergic pathways and the concentration of neurometabolites of the anterior cingulate cortex in paediatric patients with obsessive-compulsive disorder. World J. Biol. Psychiatry, 2016, 17(5), 394-404. [http://dx.doi.org/10.3109/15622975.2015.1111524]. [PMID: 26505676].
[79]
Ortiz, A.E.; Ortiz, A.G.; Falcon, C.; Morer, A.; Plana, M.T.; Bargalló, N.; Lázaro, L. 1H-MRS of the anterior cingulate cortex in childhood and adolescent obsessive-compulsive disorder: A case-control study. Eur. Neuropsychopharmacol., 2015, 25(1), 60-68. [http://dx.doi.org/10.1016/j.euroneuro.2014.11.007]. [PMID: 25499604].
[80]
Leppink, E.W.; Redden, S.A.; Grant, J.E. A double-blind, placebo-controlled study of inositol in trichotillomania. Int. Clin. Psychopharmacol., 2017, 32(2), 107-114. [http://dx.doi.org/10.1097/YIC.0000000000000156]. [PMID: 27824633].
[81]
Raynor, K.; Kong, H.; Chen, Y.; Yasuda, K.; Yu, L.; Bell, G.I.; Reisine, T. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol., 1994, 45(2), 330-334. [PMID: 8114680].
[82]
Codd, E.E.; Shank, R.P.; Schupsky, J.J.; Raffa, R.B. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J. Pharmacol. Exp. Ther., 1995, 274(3), 1263-1270. [PMID: 7562497].
[83]
Boyadjieva, N.I.; Chaturvedi, K.; Poplawski, M.M.; Sarkar, D.K. Opioid antagonist naltrexone disrupts feedback interaction between mu and delta opioid receptors in splenocytes to prevent alcohol inhibition of NK cell function. J. Immunol., 2004, 173(1), 42-49. [http://dx.doi.org/10.4049/jimmunol.173.1.42]. [PMID: 15210757].
[84]
Bailey, A.; Hawkins, R.M.; Hourani, S.M.; Kitchen, I. Quantitative autoradiography of adenosine receptors in brains of chronic naltrexone-treated mice. Br. J. Pharmacol., 2003, 139(6), 1187-1195. [http://dx.doi.org/10.1038/sj.bjp.0705340]. [PMID: 12871838].
[85]
Johansson, B.A.; Berglund, M.; Lindgren, A. Efficacy of maintenance treatment with naltrexone for opioid dependence: A meta-analytical review. Addiction, 2006, 101(4), 491-503. [http://dx.doi.org/10.1111/j.1360-0443.2006.01369.x]. [PMID: 16548929].
[86]
Miranda, R., Jr; Treloar Padovano, H.; Gray, J.C.; Wemm, S.E.; Blanchard, A. Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial. Addict. Behav., 2018, 83, 72-78. [http://dx.doi.org/10.1016/j.addbeh.2018.01.009]. [PMID: 29395188].
[87]
Mouaffak, F.; Leite, C.; Hamzaoui, S.; Benyamina, A.; Laqueille, X.; Kebir, O. Naltrexone in the treatment of broadly defined behavioral addictions: a review and meta-analysis of randomized controlled trials. Eur. Addict. Res., 2017, 23(4), 204-210. [http://dx.doi.org/10.1159/000480539]. [PMID: 28877518].
[88]
Grant, J.E.; Odlaug, B.L.; Potenza, M.N. Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome. Harv. Rev. Psychiatry, 2007, 15(2), 80-85. [http://dx.doi.org/10.1080/10673220701298407]. [PMID: 17454177].
[89]
Schlosser, S.; Black, D.W.; Blum, N.; Goldstein, R.B. The demography, phenomenology, and family history of 22 persons with compulsive hair pulling. Ann. Clin. Psychiatry, 1994, 6(3), 147-152. [http://dx.doi.org/10.3109/10401239409148996]. [PMID: 7881494].
[90]
Chamberlain, S.R.; Fineberg, N.A.; Blackwell, A.D.; Robbins, T.W.; Sahakian, B.J. Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am. J. Psychiatry, 2006, 163(7), 1282-1284. [http://dx.doi.org/10.1176/ajp.2006.163.7.1282]. [PMID: 16816237].
[91]
Li, C.S.; Huang, C.; Yan, P.; Bhagwagar, Z.; Milivojevic, V.; Sinha, R. Neural correlates of impulse control during stop signal inhibition in cocaine-dependent men. Neuropsychopharmacology, 2008, 33(8), 1798-1806. [http://dx.doi.org/10.1038/sj.npp.1301568]. [PMID: 17895916].
[92]
Dodman, N.H.; Shuster, L.; White, S.D.; Court, M.H.; Parker, D.; Dixon, R. Use of narcotic antagonists to modify stereotypic self-licking, self-chewing, and scratching behavior in dogs. J. Am. Vet. Med. Assoc., 1988, 193(7), 815-819. [PMID: 3192459].
[93]
White, S.D. Naltrexone for treatment of acral lick dermatitis in dogs. J. Am. Vet. Med. Assoc., 1990, 196(7), 1073-1076. [PMID: 2329076].
[94]
Grant, J.E.; Odlaug, B.L.; Schreiber, L.R.; Kim, S.W. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J. Clin. Psychopharmacol., 2014, 34(1), 134-138. [http://dx.doi.org/10.1097/JCP.0000000000000037]. [PMID: 24145220].
[95]
Bernardes, C.; Mattos, P.; Nazar, B.P. Skin picking disorder comorbid with ADHD successfully treated with methylphenidate. Rev. Bras. Psiquiatr., 2018, 40(1), 111. [http://dx.doi.org/10.1590/1516-4446-2017-2395]. [PMID: 29590267].
[96]
Türkoğlu, S.; Çetin, F.H. Atomoxetine in the treatment of adolescent with trichotillomania and attention-deficit/hyperactivity disorder. Clin. Neuropharmacol., 2018, 41(2), 84-85. [http://dx.doi.org/10.1097/WNF.0000000000000273]. [PMID: 29533364].
[97]
Kara, T.; Akaltun, İ. Newly developed skin picking after methylphenidate treatment in attention deficit hyperactivity disorder: possible mechanisms. Clin. Neuropharmacol., 2018, 41(1), 28-30. [PMID: 29298167].
[98]
Akaltun, İ.; Kara, T. Atomoxetine-related trichotillomania in a boy with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol., 2017, 27(10), 923. [http://dx.doi.org/10.1089/cap.2017.0113]. [PMID: 29099621].
[99]
Albert, U.; Carmassi, C.; Cosci, F.; De Cori, D.; Di Nicola, M.; Ferrari, S.; Poloni, N.; Tarricone, I.; Fiorillo, A. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int. Clin. Psychopharmacol., 2016, 31(5), 249-258. [http://dx.doi.org/10.1097/YIC.0000000000000127]. [PMID: 26974213].
[100]
Centorrino, F.; Fogarty, K.V.; Cimbolli, P.; Salvatore, P.; Thompson, T.A.; Sani, G.; Cincotta, S.L.; Baldessarini, R.J. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. J. Psychiatr. Pract., 2005, 11(4), 241-247. [http://dx.doi.org/10.1097/00131746-200507000-00004]. [PMID: 16041234].
[101]
Lostia, A.M.; Mazzarini, L.; Pacchiarotti, I.; Lionetto, L.; De Rossi, P.; Sanna, L.; Sani, G.; Kotzalidis, G.D.; Girardi, P.; Simmaco, M.; Tatarelli, R. Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response. Ther. Drug Monit., 2009, 31(4), 475-481. [http://dx.doi.org/10.1097/FTD.0b013e3181aa4780]. [PMID: 19531984].
[102]
Musenga, A.; Saracino, M.A.; Sani, G.; Raggi, M.A. Antipsychotic and antiepileptic drugs in bipolar disorder: the importance of therapeutic drug monitoring. Curr. Med. Chem., 2009, 16(12), 1463-1481. [http://dx.doi.org/10.2174/092986709787909604]. [PMID: 19355900].
[103]
Bersani, F.S.; Girardi, N.; Sanna, L.; Mazzarini, L.; Santucci, C.; Kotzalidis, G.D.; Sani, G.; De Rossi, P.; Raccah, R.N.; Caltagirone, S.S.; Battipaglia, M.; Capezzuto, S.; Bersani, G.; Girardi, P. Deep transcranial magnetic stimulation for treatment-resistant bipolar depression: a case report of acute and maintenance efficacy. Neurocase, 2013, 19(5), 451-457. [http://dx.doi.org/10.1080/13554794.2012.690429]. [PMID: 22827578].
[104]
Cocchi, L.; Zalesky, A.; Nott, Z.; Whybird, G.; Fitzgerald, P.B.; Breakspear, M. Transcranial magnetic stimulation in obsessive-compulsive disorder: A focus on network mechanisms and state dependence. Neuroimage Clin., 2018, 19, 661-674. [http://dx.doi.org/10.1016/j.nicl.2018.05.029]. [PMID: 30023172].
